Merck & Co., Inc. (MRK) - חוב לטווח ארוך להון

The share price history of Merck & Co., Inc. (MRK) demonstrates the business's dependence on the success of Keytruda and vaccines, where the key metric reaches 1.16. Despite a resilient defensive moat, the company is actively funding R&D to mitigate the risk of patent expiration. The holding's revenues are generated by medical centers purchasing innovative therapies for cancer and cardiovascular pathologies.

For Merck & Co., Inc. (MRK), amid a fierce patent race and heavy R&D expenditures, the long-term debt-to-equity ratio on GURU.Markets visualizes the balance between leveraged financing and financial autonomy. This metric compares liabilities with maturities exceeding one year against equity, where a declining value confirms the business's resilience to market shocks and its capacity to independently invest in innovation.